latest news releases from the newsroom
Pinnacle Developments, Inc.
Pinnacle Developments Announces Letter of Intent for Cantech Fibre Acquisition
VANCOUVER, British Columbia, Nov. 16, 2004 (PRIMEZONE) -- Pinnacle Developments Inc. (Pink Sheets:PNCV) is pleased to announce the signing of a letter of intent to acquire Cantech Fibre Inc., a B.C. hardwood manufacturing company. Cantech Fibre currently has a significant contract to manufacture and deliver hardwood cants for sale to China and other foreign markets. The contract specifies volumes that will ramp up over the next 90 days from 50,000 to 800,000 board feet per month. The contract is expected to generate revenues of $6,650,000 per year in gross revenues and result in $2,515,000 in earnings per year.
Wavestream Corporation Awarded Technology Innovation Award by Aviation Week
SAN DIMAS, Calif., Nov. 16, 2004 (PRIMEZONE) -- Wavestream Corporation (www.wavestreamcorp.com), a provider of innovative power amplifier solutions for today's complex communications and sensing systems, today announced that its PowerStream(tm) Grid Amplifier has been awarded the Technology Innovation Award from leading aerospace publication Aviation Week & Space Technology. PowerStream is a solid-state power amplifier which uses ground-breaking spatial power combining technology to fit big power amplifiers into small waveguide packages.
Thinkpath Announces 3rd Quarter Sales Increase of $475,000
TORONTO, Nov. 16, 2004 (PRIMEZONE) -- Thinkpath Inc. (OTCBB:THTHF) today announced that revenue from continuing operations increased in the third quarter by over $475,000 compared to the same period last year. Earnings, likewise are expected to significantly improve as gross margins increased from 33% to 37%. The third quarter financial results will be released early next week.
Crucell Discovers and Validates Human Monoclonal Antibody Product that Protects Against Rabies in Collaboration with CDC and TJU
LEIDEN, Netherlands, Nov. 16, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today the discovery and preclinical validation of an effective monoclonal antibody product for protection against rabies. The Crucell program has been performed in close collaboration with two leaders in the rabies antibody field, the Thomas Jefferson University (TJU) based in Philadelphia and the US Centers for Disease Control and Prevention (CDC) in Atlanta. This new approach may offer an alternative to Human Rabies Immune Globulin (HRIG) that is currently used in combination with a rabies vaccine in the event of exposure to this lethal disease, but which is compromised by cost, availability and safety concerns.